WO2006116681A3 - Tat-003 and methods of assessing and treating cancer - Google Patents
Tat-003 and methods of assessing and treating cancer Download PDFInfo
- Publication number
- WO2006116681A3 WO2006116681A3 PCT/US2006/016242 US2006016242W WO2006116681A3 WO 2006116681 A3 WO2006116681 A3 WO 2006116681A3 US 2006016242 W US2006016242 W US 2006016242W WO 2006116681 A3 WO2006116681 A3 WO 2006116681A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tat
- expression
- methods
- identification
- activity
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 7
- 230000000694 effects Effects 0.000 abstract 4
- 230000001093 anti-cancer Effects 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 210000000170 cell membrane Anatomy 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Surprisingly, the present inventors have discovered that expression of TAT-003 protein in human patients is associated with cancer, and that the over-expressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-003 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-003 expression or activity, comprising: contacting a candidate compound with a TAT-003 and detecting the presence or absence of binding between said compound and said TAT-003, or detecting a change in TAT-003 expression or activity. Methods are also included for the identification of compounds that modulate TAT-003 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-003 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67560305P | 2005-04-28 | 2005-04-28 | |
| US60/675,603 | 2005-04-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2006116681A2 WO2006116681A2 (en) | 2006-11-02 |
| WO2006116681A3 true WO2006116681A3 (en) | 2009-04-16 |
Family
ID=37215547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2006/016242 WO2006116681A2 (en) | 2005-04-28 | 2006-04-28 | Tat-003 and methods of assessing and treating cancer |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2006116681A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA45491A (en) * | 2016-06-27 | 2019-05-01 | Juno Therapeutics Inc | CMH-E RESTRICTED EPITOPES, BINDING MOLECULES AND RELATED METHODS AND USES |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003076578A2 (en) * | 2002-03-06 | 2003-09-18 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
-
2006
- 2006-04-28 WO PCT/US2006/016242 patent/WO2006116681A2/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003076578A2 (en) * | 2002-03-06 | 2003-09-18 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006116681A2 (en) | 2006-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1 | |
| Swayampakula et al. | The interactome of metabolic enzyme carbonic anhydrase IX reveals novel roles in tumor cell migration and invadopodia/MMP14-mediated invasion | |
| WO2009005809A3 (en) | Compositions and methods for treating and diagnosing cancer | |
| NO20074389L (en) | Determination of responders to chemotherapy | |
| CL2007003649A1 (en) | An anti-cd70 human monoclonal antibody associated molecule conjugate; composition comprising the antibody-associated molecule conjugate; method of inhibiting the growth of tumor cells expressing cd70. | |
| WO2011119934A3 (en) | Methods and materials for detecting colorectal neoplasm | |
| NO20092522L (en) | Compositions and Methods for Treating Cancer with Cupredoxins and CPG Rich DNA | |
| WO2009090553A3 (en) | Compositions and methods of detecting post-stop peptides | |
| MX2010004251A (en) | Anti-bst2 antibody. | |
| WO2006116181A3 (en) | Regulatory t cell mediator proteins and uses thereof | |
| WO2009070294A3 (en) | Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof | |
| WO2009019368A3 (en) | Method for the assay of liver fatty acid-binding protein, ace and ca19-9 for the in vitro diagnosis of colorectal cancer | |
| MX339340B (en) | Methods for predicting and improving the survival of gastric cancer patients. | |
| WO2007055966A3 (en) | Therapies for cancer using rlip76 | |
| WO2009073575A3 (en) | Methods for treating induced cellular proliferative disorders | |
| WO2007087263A3 (en) | Human zip1, zinc and citrate for prostate cancer screening | |
| WO2006083957A3 (en) | Tat-001 and methods of assessing and treating cancer | |
| Zhao et al. | Identification of a potential tumor suppressor gene, UBL3, in non-small cell lung cancer | |
| WO2005094348A3 (en) | Anti-lfl2 antibodies for the diagnosis, prognosis and treatment of cancer | |
| WO2003055908A3 (en) | Bag3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases | |
| WO2006133145A3 (en) | Tat-007 and methods of assessing and treating cancer | |
| WO2006116681A3 (en) | Tat-003 and methods of assessing and treating cancer | |
| WO2006116541A3 (en) | Tat-002 and methods of assessing and treating cancer | |
| WO2007005559A3 (en) | Tat-005 and methods of assessing and treating cancer | |
| WO2007089793A3 (en) | Tat-041 and methods of assessing and treating cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| NENP | Non-entry into the national phase |
Ref country code: RU |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 06751767 Country of ref document: EP Kind code of ref document: A2 |